PE20091827A1 - Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer - Google Patents
Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancerInfo
- Publication number
- PE20091827A1 PE20091827A1 PE2009000492A PE2009000492A PE20091827A1 PE 20091827 A1 PE20091827 A1 PE 20091827A1 PE 2009000492 A PE2009000492 A PE 2009000492A PE 2009000492 A PE2009000492 A PE 2009000492A PE 20091827 A1 PE20091827 A1 PE 20091827A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- cancer
- egf
- treatment
- hgf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN AGENTE INHIBIDOR DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (HGF) TAL COMO ANTICUERPO MONOCLONAL L2G7 HUMANIZADO; B) UN AGENTE INHIBIDOR DEL FACTOR DE CRECIMIENTO EPIDERMICO (EGF) O ANTAGONISTA DEL RECEPTOR EGF TALES COMO CETUXIMAB, PANITUMUMAB, ERLOTINIB O GEFITINIB. DICHA COMPOSICION ES UNA COMBINACION UTIL EN EL TRATAMIENTO DEL CANCER BRONCOPULMONAR, CANCER DE COLON, GLIOMA, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4444008P | 2008-04-11 | 2008-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091827A1 true PE20091827A1 (es) | 2009-11-20 |
Family
ID=41152337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009000492A PE20091827A1 (es) | 2008-04-11 | 2009-04-07 | Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer |
Country Status (7)
Country | Link |
---|---|
US (2) | US20090258014A1 (es) |
AR (1) | AR073442A1 (es) |
CL (1) | CL2009000843A1 (es) |
PE (1) | PE20091827A1 (es) |
TW (1) | TW201002346A (es) |
UY (1) | UY31757A1 (es) |
WO (1) | WO2009126834A2 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0611009A2 (pt) * | 2005-06-02 | 2010-08-10 | Galaxy Biotech Llc | usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização |
US20100113294A1 (en) * | 2007-04-16 | 2010-05-06 | Momenta Pharmaceuticals, Inc. | Defined glycoprotein products and related methods |
JP2012504606A (ja) * | 2008-10-01 | 2012-02-23 | ラディック インスティテュート フォー キャンサー リサーチ | 癌の治療方法 |
WO2010109706A1 (ja) * | 2009-03-27 | 2010-09-30 | クリングルファーマ株式会社 | 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物 |
WO2010119991A2 (en) | 2009-04-17 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Novel method of treating cancer |
WO2011119948A1 (en) * | 2010-03-26 | 2011-09-29 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
MX2012011648A (es) | 2010-04-07 | 2012-11-29 | Momenta Pharmaceuticals Inc | Glicanos de alta manosa. |
JP2013532627A (ja) * | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | cMET阻害剤とHGFおよび/またはcMETに対する抗体との組み合わせ |
US9170249B2 (en) | 2011-03-12 | 2015-10-27 | Momenta Pharmaceuticals, Inc. | N-acetylhexosamine-containing N-glycans in glycoprotein products |
CN103619881B (zh) * | 2011-04-07 | 2017-07-28 | 安姆根有限公司 | 新的egfr结合蛋白 |
WO2013181572A2 (en) * | 2012-06-01 | 2013-12-05 | Momenta Pharmaceuticals, Inc. | Methods related to panitumumab |
US9695244B2 (en) | 2012-06-01 | 2017-07-04 | Momenta Pharmaceuticals, Inc. | Methods related to denosumab |
SI2922872T1 (sl) | 2012-11-21 | 2019-01-31 | Janssen Biotech, Inc., | Bispecifična protitelesa EGFR/C-MET |
US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
EP2855533A4 (en) | 2013-03-15 | 2015-11-25 | Momenta Pharmaceuticals Inc | METHODS RELATING TO CTLA4-FC FUSION PROTEINS |
WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
AU2014334627B2 (en) | 2013-10-14 | 2019-07-25 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
TW201609805A (zh) | 2013-12-23 | 2016-03-16 | 美國禮來大藥廠 | 結合egfr及met之多功能抗體 |
BR112016021383A2 (pt) | 2014-03-24 | 2017-10-03 | Genentech Inc | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo |
EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
US10662235B2 (en) | 2016-06-21 | 2020-05-26 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
WO2018111973A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd8a-binding fibronectin type iii domains |
EP4005593A4 (en) * | 2019-07-24 | 2023-08-16 | Sinocelltech Ltd. | MULTI-VARIABLE DOSE DELIVERY METHOD FOR USE IN THE TREATMENT OF CANCER IN WHICH EGFR IS STRONGLY EXPRESSED |
CN114786682A (zh) | 2019-10-14 | 2022-07-22 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US7709454B2 (en) * | 1997-06-20 | 2010-05-04 | New York University | Methods and compositions for inhibiting tumorigenesis |
US7708998B2 (en) * | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
US7220410B2 (en) * | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
TW201319088A (zh) * | 2003-07-18 | 2013-05-16 | Amgen Inc | 對肝細胞生長因子具專一性之結合劑 |
WO2006091899A2 (en) * | 2005-02-24 | 2006-08-31 | Amgen Inc. | Epidermal growth factor receptor mutations |
AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
-
2009
- 2009-04-07 PE PE2009000492A patent/PE20091827A1/es not_active Application Discontinuation
- 2009-04-07 CL CL2009000843A patent/CL2009000843A1/es unknown
- 2009-04-07 TW TW098111515A patent/TW201002346A/zh unknown
- 2009-04-08 AR ARP090101263A patent/AR073442A1/es unknown
- 2009-04-09 WO PCT/US2009/040113 patent/WO2009126834A2/en active Application Filing
- 2009-04-09 US US12/421,556 patent/US20090258014A1/en not_active Abandoned
- 2009-04-13 UY UY031757A patent/UY31757A1/es not_active Application Discontinuation
-
2010
- 2010-12-08 US US12/963,595 patent/US20120076775A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CL2009000843A1 (es) | 2009-07-24 |
US20120076775A1 (en) | 2012-03-29 |
AR073442A1 (es) | 2010-11-10 |
US20090258014A1 (en) | 2009-10-15 |
WO2009126834A2 (en) | 2009-10-15 |
WO2009126834A3 (en) | 2009-12-30 |
TW201002346A (en) | 2010-01-16 |
UY31757A1 (es) | 2009-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20091827A1 (es) | Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer | |
CL2009000559A1 (es) | Composicion farmaceutica que comprende trastuzumab-mcc-dm1 y un agente quimioterapeutico seleccionado de un anticuerpo inhibidor de la dimerizacion de her2, un anticuerpo anti-vegf, 5-fu, carboplatino, lapatinib, abt-869, docetaxel, gdc-0941 y gne-390; y su uso para el tratamiento de un trastorno hiperproliferante. | |
ES2575152T3 (es) | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores | |
PE20090227A1 (es) | Composiciones farmaceuticas que comprenden agentes anti-beta-klotho | |
UY35013A (es) | Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos | |
CL2017002146A1 (es) | Método para la reducción de la viscosidad de un anticuerpo en el que el anticuerpo comprende una región constante de la cadena pesada de subclase igg1 humana o igg4 humana (derivada de origen humano y) que comprende la modificación de la región constante de la cadena pesada del anticuerpo de subclase igg1 humana o igg4 humana con las mutaciones i253a, h310a, y h435a (divisional solicitud no. 61-2015). | |
AR065589A1 (es) | Prediccion de respuesta a un inhibidor her | |
PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
CL2011000454A1 (es) | Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
CL2012002319A1 (es) | Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras. | |
CL2009000721A1 (es) | Combinacion que comprende un anticuerpo aislado anti-igf1r o un fragmento de fijacion de antigeno del mismo en asociacion con leucovorina y 5-fluorouracilo, leucovorina o sunitinib opcionalmente asociado con otro agente quimioterapeutico; y su uso para el tratamiento o prevencion del cancer colorectal. | |
PE20090519A1 (es) | Composicion farmaceutica que contiene n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]-metil]-fenil]-2e-2-propenamida | |
CL2014000032A1 (es) | Compuestos derivados de bencilamina, inhibidores de calicreina plasmatica; composicion farmaceutica; y su uso para el tratamiento de agudeza visual deteriorada, retinopatia diabetica, edema macular diabetico, hipotension cardiomiopatia, cancer, entre otros | |
PE20150212A1 (es) | Anticuerpos anti-trka con propiedades inhibitorias mejoradas y sus derivados | |
CL2011002943A1 (es) | Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica. | |
CL2007000311A1 (es) | Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer. | |
MX336806B (es) | Inmunoconjugados, composiciones para prepararlos, y metodos prepararlos y uso. | |
CL2013003160A1 (es) | Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros. | |
DE602007006961D1 (de) | Cgrp-rezeptorantagonisten | |
CL2012001422A1 (es) | Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
CL2009001063A1 (es) | Uso de una combinacion de un compuesto derivado de n-quinoliniloxifenil-n-fenilciclopropanodicarboxamida y un inhibidor de erbb seleccionado entre lapatinib, erlotinib, gefitinib, trastuzumab, cetuximab, para eltratamiento de canceres. | |
BR112014024017A8 (pt) | Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3 | |
CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |